Targeting cancer with small molecule kinase inhibitors

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nature Reviews. Cancer

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/nrc2559PMID 19104514PMCID PMC12406740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• PTEN-deficient cancers depend on PIK3CB

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2008cited by this paper
• A role for JAK2 mutations in myeloproliferative diseases.

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib*♦

  2008cited by this paper
• Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

  2008cited by this paper
• Identification of ALK as a major familial neuroblastoma predisposition gene

  2008cited by this paper
• The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

  2008cited by this paper
• BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

  2008cited by this paper
• Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

  2008cited by this paper
• Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

  2007cited by this paper
• A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases

  2007cited by this paper
• PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

  2007cited by this paper
• Cell cycle kinases in cancer.

  2007cited by this paper
• Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

  2007cited by this paper
• Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

  2007cited by this paper
• Emerging drugs for non-small-cell lung cancer

  2007cited by this paper
• The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

  2007cited by this paper
• Crystal Structure of the T315I Mutant of Abl Kinase

  2007cited by this paper
• A clickable inhibitor reveals context-dependent autoactivation of p90 RSK.

  2007cited by this paper
• Defining the Mechanism of Activation of AMP-activated Protein Kinase by the Small Molecule A-769662, a Member of the Thienopyridone Family*

  2007cited by this paper
• In silico design of protein kinase inhibitors: successes and failures.

  2007cited by this paper
• Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis.

  2007cited by this paper
• Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors.

  2007cited by this paper
• KIT mutations in GIST.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Ba/F3 cells and their use in kinase drug discovery

  2007cited by this paper
• Recent advances of MEK inhibitors and their clinical progress.

  2007cited by this paper
• BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.

  2007cited by this paper
• Research Article: Selectivity‐determining Residues in Plk1

  2007cited by this paper
• The selectivity of protein kinase inhibitors: a further update.

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

  2007cited by this paper
• A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

  2006cited by this paper
• Current development of mTOR inhibitors as anticancer agents

  2006cited by this paper
• N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

  2006cited by this paper
• Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

  2006cited by this paper
• A general strategy for creating

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

  2006cited by this paper
• Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

  2006cited by this paper
• Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

  2006cited by this paper
• Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.

  2006cited by this paper
• Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.

  2006cited by this paper
• A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

  2006cited by this paper
• COSMIC 2005

  2006cited by this paper
• Allosteric inhibitors of Bcr-abl–dependent cell proliferation

  2006cited by this paper
• An efficient rapid system for profiling the cellular activities of molecular libraries.

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• A general strategy for creating "inactive-conformation" abl inhibitors.

  2006cited by this paper
• Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

  2006cited by this paper
• Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.

  2006cited by this paper
• An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.

  2005cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

  2005cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

  2005cited by this paper
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

  2005cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005cited by this paper
• ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

  2005cited by this paper
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

  2005cited by this paper
• Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

  2005cited by this paper
• Structural Bioinformatics-Based Design of Selective , Irreversible Kinase Inhibitors

  2005cited by this paper
• A census of human cancer genes

  2004cited by this paper
• 90-kDa Ribosomal S6 Kinase Is a Direct Target for the Nuclear Fibroblast Growth Factor Receptor 1 (FGFR1)

  2004cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• Creating chemical diversity to target protein kinases.

  2004cited by this paper
• Prediction of Resistance to Small Molecule FLT3 Inhibitors

  2004cited by this paper
• Guilty as charged: B-RAF is a human oncogene.

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• New lead generation strategies for protein kinase inhibitors - fragment based screening approaches.

  2004cited by this paper
• A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice.

  2003cited by this paper
• An efficient proteomics method to identify the cellular targets of protein kinase inhibitors

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

  2003cited by this paper
• Structural basis for the autoinhibition of c-Abl tyrosine kinase.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• Protein kinases — the major drug targets of the twenty-first century?

  2002cited by this paper
• Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

  2002cited by this paper
• A pulsating auroral X-ray hot spot on Jupiter

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• The sequence of the human genome (abstract only)

  2001cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

  2000cited by this paper

• EGFR Mutations and Tyrosine Kinase Inhibitors: Structural Insights and Therapeutic Advances.

  2026cites this paper
• Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis.

  2026cites this paper
• Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD‐1 Inhibitor Plus TKIs in Combination of TACE for uHCC

  2026cites this paper
• Orchestrating Microtubules: A Review of Kinase–Dependent Regulatory Mechanisms

  2026cites this paper
• SOPE-MsL: Synergy-Optimized Protein Language Model Embeddings with Multiscale Learning for Interpretable Protein-Small-Molecule Binding-Site Prediction.

  2026cites this paper
• Results of a large scale study of the binding of 50 type II inhibitors to 348 kinases: The role of protein reorganization

  2026cites this paper
• Quinoline–thiazolyl hydrazone hybrids as potent EGFR-targeted anticancer agents: Synthesis, biological evaluation, and computational analysis

  2026cites this paper
• KLSD: A Curated Kinase–Ligand Database Mapping Selectivity Landscapes and Polypharmacology

  2026cites this paper
• A Decade of Decline: The Decreasing Use of Positive Controls Threatens the Reliability of In vitro Cancer Research

  2026cites this paper
• Structure-based discovery of a novel allosteric activator of ATG4B for the treatment of triple-negative breast cancer.

  2026cites this paper
• Novel universal domain-centric method for protein classification

  2026cites this paper
• Ultrasonication-assisted green synthesis, in silico EGFR-binding analysis, and cytotoxic evaluation of nitro-perimidines for non-small cell lung cancer

  2026cites this paper
• Serendipitous Discovery of a Novel Indole Derivative With Promising Multitarget Inhibitor and Its ADME Properties

  2026cites this paper
• Mutational signatures in cancer genomes alter protein sequence motifs in cellular signaling networks

  2026cites this paper
• Quantification of Conformational Changes of Kinase Regulators, Kinases, and Regulator-Kinase Complexes Using the TSR Algorithm.

  2026cites this paper
• Rationally Designed Dual Kinase Inhibitors for Management of Obstructive Sleep Apnea—A Computational Study

  2026cites this paper
• Frags2Drugs: A Novel In Silico Fragment-Based Approach to the Discovery of Kinase Inhibitors.

  2026cites this paper
• Associations Between Systemic Tyrosine Kinase Inhibitors and Development of Age-Related Macular Degeneration in Patients with Cancer.

  2026cites this paper
• Comparative chemical and biological study of essential oils and n-hexane extracts of Thymus vulgaris and Thymus serpyllum (Lamiaceae)

  2026cites this paper
• First-in-Class Dual PDGFR/Carbonic Anhydrase IX/XII Inhibitors: 6,7-Dimethoxyquinoline-Sulfonamides as Promising Antileukemic Agents.

  2026cites this paper
• Cationic Liposome Coated Phosphorylated Tyrosine Epitope Imprinted Nanoparticles as a “Direct-Occupancy-Driven” Strategy for Targeted Cancer Therapy

  2026cites this paper
• Novel Pyrido[2,3- d ]Pyrimidine Derivatives: Synthesis, In Silico and Cytotoxic Evaluation and Identification of a Potential Anticancer Agent

  2026cites this paper
• Computational molecular dynamics unveils polyphenolic luteolin and pedalitin as promising scaffolds targeting MPS1/TTK kinase for developing novel cancer therapeutics

  2025cites this paper
• Food interactions with tyrosine kinase inhibitors used to treat advanced renal cell carcinoma

  2025cites this paper
• kinCSM-RTK: Machine Learning-Based Screening of Receptor Tyrosine Kinase Inhibitors in Drug Discovery

  2025cites this paper
• Tyrosine kinase as therapeutic target of neurodegenerative disorders

  2025cites this paper
• Targeting mRNA export complex macromolecules THO subunits (Thoc2 and Thoc5) for somatic cell reprograming.

  2025cites this paper
• Inhibition of Kinase Activity and In Vitro Downregulation of the Protein Kinases in Lung Cancer and Cervical Cancer Cell Lines and the Identified Known Anticancer Compounds of Ziziphus mucronata

  2025cites this paper
• Proteomic Profiling in Colorectal Cancer: Identifying Druggable Biomarkers for Personalized Therapy

  2025cites this paper
• Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy

  2025cites this paper
• Synthesis and stability of N-ε-phospholysine derivatives

  2025cites this paper
• Small molecule kinase inhibitor altiratinib inhibits brain cyst forming bradyzoites of Toxoplasma gondii.

  2025cites this paper
• A computational tool to infer enzyme activity using post-translational modification profiling data

  2025cites this paper
• Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach.

  2025cites this paper
• Design, synthesis, and anticancer evaluation of spirooxindole-1,2,3-triazole hybrids as potent VEGFR-2 inhibitors.

  2025cites this paper
• Fused thiophene - benzimidazole conjugates targeting EGFR: Design, synthesis, anticancer evaluation and their mechanistic insights.

  2025cites this paper
• Green and sustainable approaches to Quinazoline-based anticancer agents: Synthesis and structure activity relationship (SAR).

  2025cites this paper
• Loss of Ezrin triggers mitochondrial dysfunction and oxidative stress, associated with neuronal cell death

  2025cites this paper
• Exploring Ionic Liquid-Based Methods in the Synthesis of Benzimidazole-1,3,4-Oxadiazole Derivatives for EGFR Inhibition, designed using a Comprehensive Molecular Docking and Dynamics Study

  2025cites this paper
• Design, synthesis, and in silico studies of new benzofuran–pyrazole hybrids as multi-kinase inhibitors with potential antiproliferative activity

  2025cites this paper
• 3H-pyrazolo[4,3-f]quinoline hinge binder, a tunable scaffold for development of novel kinase inhibitors against FLT3-driven leukemia.

  2025cites this paper
• ECLIPSE: Exploration of Complex Ligand-Protein Interactions through Learning from Systems-level Heterogeneous Biomedical Knowledge Graphs

  2025cites this paper
• Design, Synthesis, In Silico Evaluation, and Biological Assessment of Novel Pyrido[2,3‐d]Pyrimidine Derivatives as Potential Anticancer Agents

  2025cites this paper
• Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

  2025cites this paper
• m7G-related gene signatures determine prognosis in triple-negative breast cancer

  2025cites this paper
• Toward the Design of New α‐Carboline Derivatives Against Anaplastic Lymphoma Kinase (ALK): A Comprehensive In Silico Approach

  2025cites this paper
• Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects.

  2025cites this paper
• Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.

  2025cites this paper
• Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis

  2025cites this paper
• Tandem Synthesis and Computational Insights into Triazole and Pyrazole-Based Pyridine Derivatives Targeting EGFR-TK in Cancer Therapy

  2025cites this paper
• Targeting cyclin-dependent kinase 11: a computational approach for natural anti-cancer compound discovery

  2025cites this paper
• Calothrixin B by docking JAK2 is a potential therapeutic inhibitor for pancreatic ductal adenocarcinoma.

  2025cites this paper
• Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer

  2025cites this paper
• Cancer nanomedicine: Smart arsenal in the war against cancer

  2025cites this paper
• The Role of Protein Kinases in the Suppressive Phenotype of Myeloid-Derived Suppressor Cells

  2025cites this paper
• The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer

  2025cites this paper
• Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors

  2025cites this paper
• Dona Flor and her two husbands: Discovery of novel HDAC6/AKT2 inhibitors for myeloid cancer treatment

  2025cites this paper
• Atomic Ga Site Enables Photonanozymes with Specific Inhibition Modes for Primary Drug Screening.

  2025cites this paper
• KinaseFusionDB: an integrative knowledge of kinase fusion proteins in multi-scales

  2025cites this paper
• Computational Structural Comparison of Toxoplasma gondii CDPK1 and Human BUB1 kinases: Implications for Selective Inhibitor Design

  2025cites this paper
• Comparative Analysis of Adverse Effects: Protein Kinase Inhibitors Versus Traditional Anticancer Therapies

  2025cites this paper
• Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations

  2025cites this paper
• Casein kinase 1 epsilon (CK1ε) as a potential therapeutic target in chronic liver disease

  2025cites this paper
• A Specialized and Enhanced Deep Generation Model for Active Molecular Design Targeting Kinases Guided by Affinity Prediction Models and Reinforcement Learning

  2025cites this paper
• EGFR Inhibitors Across Generations: Progress, Challenges, and Future Directions

  2025cites this paper
• Sodium Iodide-Promoted Construction of Fully Substituted 4-Sulfenyl-5-aminopyrazole Derivatives.

  2025cites this paper
• Lysine Acetyltransferase 8: A Target for Natural Compounds in Cancer Therapy

  2025cites this paper
• Design, Synthesis, and Evaluation of Pyrrolopyrazine‐Substituted Benzoxazole/Benzothiazole Derivatives Targeting Aurora Kinase A in MCF‐7 Cells

  2025cites this paper
• Discovery of KDX1381, a Bivalent CK2α Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination.

  2025cites this paper
• Evolution of Clinical Trials of Systemic Therapies for Hepatocellular Carcinoma Between 2005 and 2024: Based on ClinicalTrials.gov

  2025cites this paper
• Hybrid Molecules with Purine and Pyrimidine Derivatives for Antitumor Therapy: News, Perspectives, and Future Directions

  2025cites this paper
• Elacridar improves sunitinib efficacy in colorectal cancer models.

  2025cites this paper
• Design, synthesis, and anti-hepatocellular carcinoma activity evaluation of aryl Lenvatinib derivatives: Exploring potential VEGFR-2 inhibitors.

  2025cites this paper
• A novel 5-protein kinase risk signature for predicting glioma prognosis and immunotherapy responsiveness

  2025cites this paper
• RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

  2025cites this paper
• From Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy

  2025cites this paper
• Phosphoprotein Profile of Ameloblastoma

  2025cites this paper
• A homogeneous mass-encoded strategy for mass spectrometric biosensing of multiplex proteins.

  2025cites this paper
• Design and synthesis of novel cyclin-dependent kinase 4/6(CDK4/6) and histone deacetylase (HDAC) dual inhibitors: In vitro and in vivo anticancer activity.

  2025cites this paper
• WNK1 promotes head and neck squamous cell carcinoma progression through activation of NF-κB signaling pathway

  2025cites this paper
• Multi-Kinase Inhibition by New Quinazoline–Isatin Hybrids: Design, Synthesis, Biological Evaluation and Mechanistic Studies

  2025cites this paper
• Iatrogenic effect of immune checkpoint inhibitors and targeted therapies on the lower gastrointestinal tract

  2025cites this paper
• DeepEGFR a graph neural network for bioactivity classification of EGFR inhibitors

  2025cites this paper
• Automated Iterative N─C and C─C Bond Formation

  2025cites this paper
• A functional map of CDK-drug interactions at single amino acid resolution

  2025cites this paper
• Aligning organ-specific toxicities with formulation strategies: a rational design approach to chemotherapy optimization.

  2025cites this paper
• Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer

  2024cites this paper
• Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node

  2024cites this paper
• Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

  2024cites this paper
• Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation

  2024cites this paper
• Advances in the treatment of relapsed/refractory marginal zone lymphoma

  2024cites this paper
• Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation

  2024influential citation
• Kinases in motion: impact of protein and small molecule interactions on kinase conformations

  2024cites this paper
• TENT5A Increases Glioma Malignancy and Promotes its Progression.

  2024cites this paper
• Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology

  2024cites this paper
• Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development.

  2024cites this paper
• 1,2,4-Triazole-Tethered Indolinones as New Cancer-Fighting Small Molecules Targeting VEGFR-2: Synthesis, Biological Evaluations and Molecular Docking

  2024cites this paper
• Design, Synthesis, and Bioevaluation of Novel Reversibly Photoswitchable PI3K Inhibitors Based on Phenylazopyridine Derivatives toward Light-Controlled Cancer Treatment.

  2024cites this paper
• The Druggable Target Potential of NF-κB-Inducing Kinase (NIK) in Cancer

  2024cites this paper